Roche nabs breakthrough tag for TIGIT cancer immunotherapy
pharmaphorum
JANUARY 5, 2021
First-line immunotherapy for NSCLC is dominated by Merck & Co’s PD-1 inhibitor Keytruda (pembrolizumab), transforming the prospects of some patients and propelling the drug to multibillion-dollar sales. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.
Let's personalize your content